FAQs
DIANTHUS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE PHASE 1 DATA AND DEBUTS TRADING ON NASDAQ AS DNTH
Show All
On which exchange is Dianthus Therapeutics listed, what is the ticker symbol and when did it go public?
Dianthus Therapeutics’ stock is traded on the Nasdaq Capital Market under the symbol “DNTH”. The Company went public via a merger with Magenta Therapeutics, Inc. (MGTA) on September 11, 2023.
Where is the Dianthus Therapeutics corporate headquarters?
Dianthus Therapeutics is headquartered at 7 Times Square, New York, New York, 10036.
When is Dianthus Therapeutics’ fiscal year-end?
Dianthus Therapeutics’ fiscal year-end is December 31st.
Who is Dianthus Therapeutics’ transfer agent?
Dianthus Therapeutics’ transfer agent is Computershare.
150 Royall Street
Canton, MA 02021
800-446-2617
Who is Dianthus Therapeutics’ legal counsel?
Dianthus Therapeutics’ legal counsel is Gibson, Dunn & Crutcher LLP
Who is Dianthus Therapeutics’ independent auditor?
Dianthus Therapeutics’ auditor is Deloitte in Morristown, NJ.
Where can I find the latest corporate news releases and financial reports?
Dianthus Therapeutics’ press release archives can be viewed here.
Where can I find copies of Dianthus Therapeutics’ financial documents, including annual reports (Form-10K) and quarterly reports (Form 10-Q)?
Dianthus Therapeutics’ SEC filings can be found on https://www.sec.gov and can be viewed here.
When and where is the Annual Stockholders’ Meeting?
Our stockholders’ meeting will be held annually. Instructions on how to attend will be delivered to all stockholders.
Whom should I contact regarding investor inquiries?
Please email ir@dianthustx.com for assistance.
Where can I find out more about Dianthus Therapeutics?
To find out more about us, visit our webpage at dianthustx.com or sign up here to receive email alerts.